GlobeNewsWire
22 Jul 2026, 19:48 UTC · 1h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
3 claims · each scored for market impact
ADMA Biologics is facing a securities class action lawsuit alleging the use of channel stuffing to artificially inflate revenue. — Allegations of revenue manipulation (channel stuffing) strike at the core of financial integrity and typically lead to significant share price declines.
-0.80The lawsuit claims ADMA Biologics engaged in undisclosed related party transactions and lacked adequate internal controls. — Poor internal controls and undisclosed related-party deals suggest governance failures and increase the risk of further financial irregularities.
-0.60The deadline for investors to move the court to serve as lead plaintiff in the ADMA Biologics class action is August 10, 2026. — While a procedural deadline, it maintains the legal pressure on the company and keeps the litigation active in the public eye.
-0.10Which stocks this story touches
Continue reading
6 related stories
Search tags
The company is facing a securities class action lawsuit alleging channel stuffing, undisclosed related party transactions, and lack of internal controls.
The company is mentioned in the context of a reminder for purchasers of securities regarding a potential legal action.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
